Genmab To Expand Proprietary Pipeline, Closing In On Marketing Its Own Products
Updates Financial Guidance For 2021
Executive Summary
The antibody discovery and development biotech Genmab is preparing to commercialize its own products in the second half of 2021, as revenues continue to grow from partners and licensees.
You may also be interested in...
Blow To Genmab As It Is Set To Lose Darzalex Royalties Sooner Than Hoped
The Danish firm will stop receiving royalties on Darzalex after 2030 having has lost on two issues heard at an arbitration tribunal, in a significant blow to its finances.
J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers
The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.